ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0887

Association of Mycophenolate and Azathioprine Use with Cognitive Function in SLE

Chrisanna Dobrowolski1, Jiandong Su2, John McGinley1, Melissa Fazzari1, Kathleen Bingham3, Nicole Anderson2, Dorcas Beaton4, Lesley Ruttan3, Joan Wither2, Maria Tartaglia2, Mahta Kakvan2, Dennisse Bonilla2, May Choi5, Marvin Fritzler6, Patricia Katz7, Robin Green2, Chaim Putterman1 and Zahi Touma8, 1Albert Einstein College of Medicine, Bronx, NY, 2University Health Network, Toronto, ON, Canada, 3University of Toronto, University Health Network, Toronto, ON, Canada, 4Institute for Work & Health, Toronto, ON, Canada, 5Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, 6University of Calgary, Calgary, AB, Canada, 7University of California San Francisco, San Francisco, CA, 8University of Toronto, Mississauga, ON, Canada

Meeting: ACR Convergence 2021

Keywords: azathioprine, Cognitive dysfunction, neuropsychiatric systemic lupus erythematosus (NPSLE), Neuropsychological Assessment, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Cognitive dysfunction (CD) is a common manifestation of systemic lupus erythematosus (SLE) which can have detrimental consequences for those affected. To date, no treatments have been approved for SLE-associated CD (SLE-CD). This study aims to assess the association of azathioprine (AZA) and mycophenolate (MMF) use with SLE-CD, given that these medications have demonstrated neuroprotective qualities in prior studies.

Methods: Consecutive adult SLE patients presenting to a single center were screened. The American College of Rheumatology (ACR) neuropsychological battery (NB) for SLE, evaluating 6 cognitive domains, was administered to consenting participants at 0, 6 and 12 months. Age and gender matched normative data were used to obtain z-scores. CD was determined by a z-score of £-1.5 in ³2 cognitive domains. Non-CD was defined as no z-score £-1.5. MMF and AZA use were recorded as cumulative dose (grams per kilogram [g/kg]), duration of treatment (number of years) and current use for ³6 months from visit day. Clinical and demographic characteristics were verified at each visit. Baseline characteristics by cognitive status and medication use were documented. Mixed-effects logistic regression models were constructed to estimate the odds of CD and non-CD with respect to AZA and MMF use over the three follow-up periods.

Results: Three hundred participants representing 676 patient visits completed the study; 157 (52%) met criteria for CD at baseline. Mean age was 41.1 years (SD 12.1) and 267 participants (89.0%) were female. Table 1 outlines baseline characteristics by CD and non-CD status. There were no significant differences in mean age, glucocorticoid dose, disease duration, SLE Disease Activity Index-2000 (SLEDAI-2K) scores, or SLICC-ACR Damage Index (SDI) scores. In contrast, there were significantly more participants with CD who identified as Black or Chinese, and significantly fewer participants identifying as White. There were also fewer married participants with CD. Table 2 documents baseline characteristics by AZA and MMF use with respect to CD status. Participants taking AZA or MMF had significantly higher SLEDAI-2K scores and higher prevalence of nephritis; participants taking MMF had higher rates of hypertension, higher daily doses of glucocorticoid medications and lower rates of smoking.

Table 3 shows results of the mixed effects models for AZA and MMF use versus CD. For each g/kg of cumulative AZA, there was on average a 24% reduced odds of CD: OR 0.76, 95% CI 0.61, 0.96, p=0.02. For each year of AZA treatment there was on average a 32% reduced odds of CD: OR 0.68 (0.50, 0.94), p=0.02. AZA use as binary variable (yes versus no) demonstrated a consistent trend toward reduced odds of CD with AZA use without reaching statistical significance: OR 0.29 (0.08, 1.12), p=0.07. Cumulative AZA dose was not significantly associated with non-CD status: 1.08 (0.91, 1.27), p=0.38 (not shown). MMF use was not associated with CD or non-CD.

Conclusion: Despite higher disease activity scores in participants taking AZA compared to those not taking AZA, cumulative AZA dose and increasing AZA treatment duration were associated with significantly lower odds of SLE-CD. MMF use was not associated with SLE-CD.

1) CD: cognitive dysfunction. Defined as a z-score of ≤_1.5 on ≥2 cognitive domains, based on neuropsychological testing.
2) Completion of post-secondary schooling including a College (≥2 years) or University (≥4 years) degree.
3) Positive lupus anticoagulant testing, and/or anti-beta2glycoprotein1 IgG or IgM, and/or anti-cardiolipin IgG or IgM above laboratory specific upper limit of normal, at baseline and again after ≥12 weeks.
4) Psychosis, seizures, stroke, neuropathy and/or transverse myelitis.
5) Known risk factors for cognitive dysfunction not captured elsewhere.
6) SLICC ACR: Systemic Lupus International Collaborating Clinics / American College of Rheumatology Damage Index.
7) SLEDAI_2K: Systemic Lupus Erythematosus Disease Activity Index 2000.
8) SLEDAI_2KG: Systemic Lupus Erythematosus Disease Activity Index 2000 Glucocorticoid Index.
9) Beck Depression Inventory score of 0–13 is considered minimal, 14–19 mild, 20–28 moderate and 29–63 severe.
10) Beck Anxiety Inventory score of 0-7 is considered minimal, 8_15 mild, 16_25 moderate and 26-63 severe.

AZA: azathioprine; MMF: mycophenolate; CD: cognitive dysfunction; NPSLE: neurologic and psychiatric manifestations of systemic lupus.
1) SLICC-ACR DI: Systemic Lupus International Collaborating Clinics American College of Rheumatology Damage Index.
2) SLEDAI_2K: Systemic Lupus Erythematosus Disease Activity Index 2000.
3) SLEDAI_2KG: Systemic Lupus Erythematosus Disease Activity Index 2K Glucocorticoid.
4) Positive lupus anticoagulant testing, and/or anti-beta2glycoprotein1 IgG or IgM, and/or anti-cardiolipin IgG or IgM above laboratory specific upper limit of normal, at baseline and again after ≥12 weeks
5) Psychosis, seizures, stroke, neuropathy and/or transverse myelitis.
6) Known risk factors for cognitive dysfunction not captured elsewhere.

1Cognitive dysfunction was defined as a z-score of ≤_1.5 on ≥2 cognitive domains based on comprehensive neuropsychological testing.
OR: odds ratio; CI: confidence interval.

Covariates included in the models: Systemic Lupus Erythematosus Disease Activity Index_2000 Glucocorticoid (SLEDAI_2KG) score (incorporates glucocorticoid dose with the SLE Disease Activity Index 2000 [SLEDAI_2K]), Systemic Lupus International Collaborating Clinics (SLICC) – American College of Rheumatology (ACR) Damage Index score (SDI), additional CD risk factors not captured elsewhere (hypertension, obesity, active smoker), persistent antiphospholipid antibody positivity (positive lupus anticoagulant testing, and/or anti-beta2glycoprotein1 IgG or IgM, and/or anti-cardiolipin IgG or IgM above laboratory specific upper limit of normal, at baseline and again after ≥12 weeks, recorded as binary variable), history of lupus nephritis, active use of an additional immunomodulator (antimalarials, belimumab, calcineurin inhibitor, cyclophosphamide, methotrexate, rituximab), prior use of an immunomodulator (AZA, calcineurin inhibitor, cyclophosphamide, methotrexate, MMF), Beck Depression Inventory (BDI) scores, Beck Anxiety Inventory (BAI) scores, age in years, sex (male versus female), ethnicity (Black, Caucasian, Chinese or other), education level (completion of a College or University degree recorded as binary variable), employment status (employed or full time student versus other) and marital status (married or common-law partner versus other).


Disclosures: C. Dobrowolski, None; J. Su, None; J. McGinley, None; M. Fazzari, None; K. Bingham, None; N. Anderson, None; D. Beaton, None; L. Ruttan, None; J. Wither, None; M. Tartaglia, None; M. Kakvan, None; D. Bonilla, None; M. Choi, MitogenDx, 1, 2; M. Fritzler, Inova Diagnostics Inc., 2, 6, Werfen International, 2, Alexion Canada, 6, Mitogen Diagnostics Corp., 3, 8, 9, 10; P. Katz, None; R. Green, None; C. Putterman, equllium, 2, 5, Progentec, 2, Kidneycure, 2; Z. Touma, AbbVie Inc, 2, UCB Biopharma SRL, 2, Sarkana Pharma Inc., 1, 4, Janssen Inc., 2, GlaxoSmithKline Inc., 6.

To cite this abstract in AMA style:

Dobrowolski C, Su J, McGinley J, Fazzari M, Bingham K, Anderson N, Beaton D, Ruttan L, Wither J, Tartaglia M, Kakvan M, Bonilla D, Choi M, Fritzler M, Katz P, Green R, Putterman C, Touma Z. Association of Mycophenolate and Azathioprine Use with Cognitive Function in SLE [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/association-of-mycophenolate-and-azathioprine-use-with-cognitive-function-in-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-mycophenolate-and-azathioprine-use-with-cognitive-function-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology